Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
The narrative spans four generations, highlighting the hereditary nature of breast cancer and its impact on family dynamics.
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...
Goshen Center for Cancer Care is recognizing the completion of 50 procedures utilizing cutting-edge robotic technology to provide a less invasive option to biopsy lung lesions. The Galaxy System is a ...
All women should start mammograms at age 40 to screen for breast cancer, regardless of family history. Sponsored by Virginia Mason Franciscan Health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback